Brought to you by 
Baxter pays $60mm up front for exclusive rights to CTI's Phase III pacritinib; rights returned
09 Nov 2016
Executive Summary
Baxter International Inc. licensed exclusive rights to develop and sell oncology firm Cell Therapeutics Inc.’s pacritinib, a Phase III JAK2/FLT3 inhibitor for myelofibrosis, leukemia, and solid tumors. The companies will co-promote in the US. CTI originally gained global pacritinib rights from SBIO in April 2012.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Baxter pays $60mm up front for exclusive rights to CTI's Phase III pacritinib; rights returned
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice